Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
Ki Y. Chung(Prisma Health), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Audrey Hamilton(Memorial Sloan Kettering Cancer Center), David S. Klimstra(Yale University), Daniel Fridman(Memorial Sloan Kettering Cancer Center), Lawrence B. Schwartz(Memorial Sloan Kettering Cancer Center), Nancy E. Kemeny(Memorial Sloan Kettering Cancer Center), David P. Kelsen(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Deborah Schrag(Dana-Farber Brigham Cancer Center), Manish A. Shah(NewYork–Presbyterian Hospital), Gary K. Schwartz(Baylor University Medical Center), Archie Tse(Brunswick (United States)), Dorothy W. Pan(Memorial Sloan Kettering Cancer Center)
Cited by 1,083
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k